SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-24-078791 from Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)

Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Date: March 27, 2024 · CIK: 0001501756 · Accession: 0001193125-24-078791

AI Filing Summary & Sentiment

File numbers found in text: 333-278157

Date
March 27, 2024
Author
Not clearly detected
Form
CORRESP
Company
Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)

Letter

ADVERUM BIOTECHNOLOGIES, INC.

100 Cardinal Way

Redwood City, California 94063

March 27, 2024

VIA EMAIL AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3010

Attn: Jason Drory

RE: Adverum Biotechnologies, Inc.

Registration Statement on Form S-3 (File No. 333-278157)

Request for Acceleration of Effective Date

Ladies and Gentlemen:

Adverum Biotechnologies, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-278157) (the “Registration Statement”) to become effective on Friday, March 29, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Kenneth Guernsey and Julia Boesch of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Julia Boesch of Cooley LLP, counsel to the Registrant, at (415) 693-2326, or in her absence, Kenneth Guernsey at (415) 693-2091.

[Remainder of page intentionally left blank]

Very truly yours,
ADVERUM BIOTECHNOLOGIES, INC.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 ADVERUM BIOTECHNOLOGIES, INC.

100 Cardinal Way

 Redwood City,
California 94063

 March 27, 2024

VIA EMAIL AND EDGAR

U.S. Securities and Exchange Commission

 Division of Corporation
Finance

 100 F Street, N.E.

 Washington, D.C. 20549-3010

Attn:
 Jason Drory

RE:
 Adverum Biotechnologies, Inc.

Registration Statement on Form S-3 (File No. 333-278157)

Request for Acceleration of Effective Date

Ladies and Gentlemen:

 Adverum Biotechnologies,
Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-278157) (the “Registration Statement”) to become effective on Friday, March 29, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable or at
such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Kenneth Guernsey and Julia Boesch of Cooley LLP, counsel to the Registrant, to make such request on its
behalf.

 Once the Registration Statement has been declared effective, please orally confirm that event with Julia Boesch of Cooley LLP,
counsel to the Registrant, at (415) 693-2326, or in her absence, Kenneth Guernsey at (415) 693-2091.

[Remainder of page intentionally left blank]

Very truly yours,

ADVERUM BIOTECHNOLOGIES, INC.

By:

 /s/ Linda Rubinstein

Name:

Linda Rubinstein

Title:

Chief Financial Officer

cc:
 Kenneth Guernsey, Cooley LLP

Julia Boesch, Cooley LLP